


SYNTHESIS AND CYTOTOXIC ACTIVITY OF ALKYLIDENE- AND ALKYL-SUBSTITUTED CAMPTOTHECINS.

Ilaria Candiani, Angelo Bedeschi,^{*} Walter Cabri,¹ Franco Zarini, Giuseppina Visentin,
Laura Capolongo, Cristina Geroni, Marina Ciomei.

Pharmacia & Upjohn, Oncology, Via Pasteur 10, 20014 Nerviano (MI), Italy

Abstract: A new family of camptothecin derivatives is described. Their synthesis, *in vitro* cytotoxicity, and topoisomerase I inhibition is reported. © 1997 Elsevier Science Ltd.

Camptothecin (**1**), firstly isolated by Wani and Wall from *Camptotheca Acuminata*,² is a potent inhibitor of DNA topoisomerase I.³ Some of its derivatives⁴ are on the market as anticancer drugs in Europe, USA and Japan. Among them 9-amino camptothecin⁵ (9-AC, **2**) has emerged as one of the most promising clinical candidates for cancer treatment. During the course of our work aimed to the synthesis of 9-AC (**2**), we developed a Pd(0) catalysed deoxygenation on **3**.⁶ Accordingly, we decided to extend the Pd(0) catalysis to C-C bond formation, by the use of the Heck reaction.⁷ Now we wish to report the synthesis, and the preliminary *in vitro* cytotoxicity, of a new series of camptothecin analogs (**6**), derived from the application of the Heck reaction to the camptothecin nucleus. Compounds (**6**) are endowed with good *in vitro* cytotoxicity.




- 1** R₁ = H, R₂ = H
- 2** R₁ = 9-NH₂, R₂ = H
- 3** R₁ = 10-OH, R₂ = H
- 4** R₁ = 9-Br, R₂ = H
- 5** R₁ = 10-OTf, R₂ = H
- 5a** R₁ = 10-OTs, R₂ = 9-NO₂

The Heck reaction on a CPT nucleus lacking an activating group (such as nitro group in **5a**) required use of a leaving group better than tosylate and the choice of the proper reaction conditions and phosphine ligands. Compounds of formula **6a-g** were synthesised from halogeno- or trifluoromethansulfonyl- camptothecins of formula **4** and **5** (scheme 1).⁸ Reaction of 9-Br-CPT (**4**) in DMF at 100°C overnight with methyl acrylate and acrylamide in presence of Pd(OAc)₂, and 1,1'-bis-(diphenylphosphino)ferrocene (DPPF) as ligand, afforded **6a**,⁹ and **6b** in 70%, and 53% yield respectively. The reaction of **4** with methyl 2-acetamidoacrylate in the same conditions was faster (4 hours) and afforded **6c** in 78%y. Only the Z form was present, while a slow (2 weeks) equilibration E/Z took place when **6c** was dissolved in DMSO. Trimethyl vinyl silane reacted in one hour to

^{*} E-Mail: angelo.bedeschi@eu.pnu.com - Fax: +39 2 4838.3833

give a mixture of **6e** (50%y.) and **6f** (25%y.), that could be easily separated. **6f** was obtained also from a brief treatment of **6e** with trifluoroacetic acid.

Scheme 1.



9-derivatives

6a $R_1 = \text{COOMe}$, $R_2 = \text{H}$;

6b $R_1 = \text{CONH}_2$, $R_2 = \text{H}$;

6c $R_1 = \text{COOMe}$, $R_2 = \text{NHCOCH}_3$;

6d $R_1 = \text{Ph}$, $R_2 = \text{H}$;

6e $R_1 = \text{Si}(\text{Me})_3$, $R_2 = \text{H}$;

6f $R_1 = \text{H}$, $R_2 = \text{H}$;

10-derivatives


6g $R_1 = \text{COOMe}$, $R_2 = \text{H}$;

i: 16% HBr, NaNO_2 , rt; CuBr, 16% HBr, 70°C, 2hs; ii: Et_3N , CH_2Cl_2 , Tf_2O , 0°C; iii: DMF, 5% mol. $\text{Pd}(\text{OAc})_2$, 5.5% mol. Dppf, 100 °C, alkene 5 mol. equiv., 53-78% y.

The reaction with styrene was complete in 5 hours to give **6d** (63%y.). Reaction of **5** in DMF at 80°C with methylacrylate and $\text{Pd}(\text{OAc})_2$ /DPPF as catalytic system gave, after 24 hrs, **6g** (57%y.). Addition of one equivalent of LiCl or NaOAc did improve the reactivity,¹⁰ being the reaction complete respectively in 1 and 3 hours, but led to the formation of inseparable by-products. In all cases in compounds **6a-g**, when $R_2 = \text{H}$, the E form was formed exclusively.

Eventually some selected compounds (**6a**, **6c**, and **6d**) were reduced under classical conditions (Pd/C, room temperature) to afford the corresponding alkyl derivatives **7a-c**,⁹ according to scheme 2.

Scheme 2.



7a $R_1 = \text{COOMe}$, $R_2 = \text{H}$;

7b $R_1 = \text{COOMe}$, $R_2 = \text{NHCOCH}_3$;

7c $R_1 = \text{Ph}$, $R_2 = \text{H}$;

Table 1 presents the *in vitro* cytotoxic activity on L1210 murine leukemia cells¹¹ and the topoisomerase I inhibition¹² of some selected derivatives **6**.

The introduction in 9 position of the camptothecin nucleus of an unsubstituted alkylidene moiety, as in **6f**, provides a compound endowed with a cytotoxic activity comparable to 9-AC. The 2-substitution on the alkenyl residue also influenced the overall cytotoxicity. The presence of a polar amide group (**6b-c**) led to a decrease in cytotoxic activity in respect to the parent compound and to less polar or non polar substituents (**6a** and **6d**). Substitution in 10 position also led to a decrease in cytotoxic activity (**6a** vs. **6g**).

Table 1. *In vitro* activity against L1210 murine leukemia cells and relaxation activity inhibition of topoisomerase I of selected camptothecin derivatives **6**.

Compound	Cytotoxicity on L1210 IC ₅₀ ^{a)} (nM ± S.E.)	Topo I inhibition IC ₅₀ ^{b)} (μM ± S.E.)
6a	7.6 ± 4.1	6.7 ± 3.1
6b	121.1 ± 13.2	3.2 ± 0.9
6c	1184.9 ± 286.8	31.9 ± 7.3
6d	15.8 ± 1.3	> 100
6f	7.5 ± 0.3	4.2 ± 1.7
6g	62.3 ± 11.8	> 100
9-AC (2)	12.7 ± 0.7	1.8 ± 0.8

a) Concentration inhibiting 50% of cell growth after 48h continuous treatment. b) Concentration inhibiting by 50% the relaxation of 250 ng of SV40 DNA obtained with 0.5 U topoisomerase I at 37°C for 30 min.

Table 2 presents the *in vitro* cytotoxic activity on L1210 murine leukemia cells¹¹ and the topoisomerase I inhibition¹² of derivatives **7a-c**. The reduction of the alkylidene double bonds of **6a** and **6d** to afford the more flexible, non conjugated alkyl substituted derivatives **7a** and **7c** did not lead to relevant differences in cytotoxicity in respect to the parent compounds. A five fold increase in cytotoxicity was instead observed in **7b** compared to the parent **6c**. In both series there was no correlation between cytotoxicity and topoisomerase I inhibiting activity. In this respect other factors, like the ability of the compounds to accumulate into the cells and to maintain sustained intracellular levels, could play an important role.

Table 2. *In vitro* activity against L1210 murine leukemia cells and relaxation activity inhibition of topoisomerase I of camptothecins **7a-c**.

Compound	Cytotoxicity on L1210 IC ₅₀ ^{a)} (nM ± S.E.)	Topo I inhibition IC ₅₀ ^{b)} (μM ± S.E.)
7a	6.2 ± 1.1	41.8 ± 3.8
7b	183.1 ± 32.6	11.3 ± 2.3
7c	16.3 ± 1.3	> 100
9-AC (2)	12.7 ± 0.7	1.8 ± 0.8

a) Concentration inhibiting 50% of cell growth after 48h continuous treatment. b) Concentration inhibiting by 50% the relaxation of 250 ng of SV40 DNA obtained with 0.5 U topoisomerase I at 37°C for 30 min.

Further work is in progress to gain a more precise picture of the structure-activity relationships and of the mechanism of action in this class of compounds and to ascertain their antitumor activity on selected tumor models.

References and notes.

1. Present address: SECIFARMA SpA, Via Bissone 5, Baranzate di Bollate (MI), Italy.
2. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. *J. Am. Chem. Soc.* **1966**, *88*, 3888.
3. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. *J. Biol. Chem.* **1985**, *260*, 14873. Hsiang, Y. H.; Liu, L. F.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Kirshenbaum, S.; Silber, R.; Potmesil, M. *Cancer Res.* **1989**, *49*, 4385.
4. Johnson, P. K.; McCabe, F. L.; Faucette, L. F.; Hertzberg, R. P.; Kingsbury, W. D.; Boehm, J. C.; Caranfa, M. J.; Holden, K. G. *Proc. Am. Assoc. Cancer Res.* **1989**, *30*, 623. Fukuoka, M.; Negoro, S.; Niitani, H.; Taguchi, T. *Proc. Am. Soc. Clin. Oncol.* **1990**, *9*, 874. Kingsbury, W. D.; Boehm, J. C.; Jakas, D., R.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K.; Hertzberg, R. P. *J. Med. Chem.* **1991**, *34*, 98.
5. Wani, M. C.; Nicholas, A. W.; Wall, M. E. *J. Med. Chem.* **1986**, *29*, 2358. Slichenmyer, W. J.; Rowinsky, E. K.; Donehower, R. C.; Kaufmann, S. H. *J. Natl. Canc. Inst.* **1993**, *85*, 271.
6. Cabri, W.; Candiani, I.; Zarini, F.; Penco, S.; Bedeschi, A. *Tetrahedron Letters* **1995**, *36*, 9197.
7. Heck, R. F. *org. React. (N.Y.)* **1982**, *27*, 345. De Meijere, A.; Meyer, F. E.; *Angew. Chem. Int. Ed. Engl.* **1994**, *33*, 2379. Cabri, W.; Candiani, I. *Acc. Chem. Res.* **1995**, *25*, 2.
8. Sawada, S.; Matsuoka, S.; Nokata, K.; Nagata, H.; Furuta, T.; Yokokura, T.; Miyasaka, T. *Chem. Pharm. Bull.* **1991**, *39*, 3183. The 10-trifluoromethansulfonate **5** was prepared according to scheme 1.
9. Spectral data of representative compounds. **6a**: ^1H NMR (DMSO- d_6) δ , ppm: 9.07 (1H, s); 8.45 (1H, d, J = 15.5 Hz); 8.23 (1H, d, J = 8.5 Hz); 8.14 (1H, d, J = 7.1 Hz); 7.88 (1H, dd, J = 7.6 and 8.2 Hz); 7.34 (1H, s); 6.8 (1H, d, J = 15.7 Hz); 6.53 (1H, s); 5.42 (2H, s); 5.27 (2H, s); 3.79 (3H, s); 1.86 (2H, m); 0.87 (3H, t, J = 7.32 Hz). **7c**: ^1H NMR (DMSO- d_6) δ , ppm: 8.89 (1H, s); 8.03 (1H, d, J = 8.49 Hz); 7.79-7.73 (1H, m); 7.55 (1H, d, J = 7.03 Hz); 7.33 (1H, s); 6.51 (1H, s); 5.42 (2H, s); 5.28 (2H, s); 3.59 (3H, s); 3.42-3.36 (2H, m); 2.88-2.77 (2H, m); 1.91-1.80 (2H, m); 0.87 (3H, t, J = 7.33 Hz).
10. Cabri, W.; Candiani, I.; Debernardinis, S.; Francalanci, F.; Penco, S.; Santi, R. *J. Org. Chem.* **1991**, *56*, 5796.
11. The assay for cytotoxic activity was carried out according to a procedure previously described: Geroni, C.; Pesenti, E.; Tagliabue, G.; Ballinari D.; Mongelli, N.; Brogini, M.; Erba, E.; D'Incalci, M.; Spreafico, F.; Grandi, M. *Int. J. Cancer* **1993**, *53*, 308.
12. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. *Cancer Res.* **1989**, *49*, 1465.

(Received in Belgium 5 December 1996; accepted 21 February 1997)